 Fernando Holguin
Concepts (590)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 114 | 2024 | 2257 | 12.310 |
Why?
| | Obesity | 31 | 2024 | 2851 | 3.660 |
Why?
| | Air Pollutants | 18 | 2018 | 316 | 2.840 |
Why?
| | Vehicle Emissions | 11 | 2017 | 54 | 2.330 |
Why?
| | Anti-Asthmatic Agents | 10 | 2021 | 377 | 2.090 |
Why?
| | Citrulline | 3 | 2023 | 45 | 1.980 |
Why?
| | Nitric Oxide | 16 | 2020 | 894 | 1.930 |
Why?
| | Lung | 25 | 2023 | 3928 | 1.670 |
Why?
| | Air Pollution | 11 | 2020 | 223 | 1.520 |
Why?
| | Minority Groups | 3 | 2021 | 246 | 1.390 |
Why?
| | Environmental Exposure | 13 | 2020 | 479 | 1.370 |
Why?
| | Arginine | 5 | 2023 | 256 | 1.360 |
Why?
| | Adrenal Cortex Hormones | 18 | 2021 | 526 | 1.340 |
Why?
| | Metabolic Syndrome | 4 | 2019 | 339 | 1.300 |
Why?
| | Lung Diseases | 5 | 2021 | 757 | 1.240 |
Why?
| | September 11 Terrorist Attacks | 2 | 2021 | 30 | 1.130 |
Why?
| | Humans | 145 | 2024 | 129706 | 1.110 |
Why?
| | Patient Selection | 2 | 2021 | 685 | 1.110 |
Why?
| | Bronchial Hyperreactivity | 3 | 2015 | 105 | 1.110 |
Why?
| | Dietary Supplements | 5 | 2019 | 534 | 1.040 |
Why?
| | Hospitalization | 8 | 2020 | 2091 | 1.020 |
Why?
| | Inflammation | 14 | 2020 | 2705 | 1.000 |
Why?
| | Oxidative Stress | 8 | 2022 | 1222 | 0.990 |
Why?
| | Forced Expiratory Volume | 16 | 2021 | 508 | 0.980 |
Why?
| | Respiratory Sounds | 3 | 2021 | 121 | 0.980 |
Why?
| | Adult | 71 | 2024 | 35596 | 0.960 |
Why?
| | Particulate Matter | 10 | 2020 | 245 | 0.920 |
Why?
| | Severity of Illness Index | 22 | 2021 | 2783 | 0.900 |
Why?
| | Pulmonary Medicine | 3 | 2021 | 79 | 0.890 |
Why?
| | Bronchodilator Agents | 9 | 2023 | 253 | 0.880 |
Why?
| | Glucocorticoids | 4 | 2020 | 573 | 0.880 |
Why?
| | Mucus | 1 | 2021 | 74 | 0.850 |
Why?
| | Respiratory Function Tests | 11 | 2020 | 594 | 0.830 |
Why?
| | Adrenergic beta-Agonists | 3 | 2020 | 132 | 0.820 |
Why?
| | Middle Aged | 54 | 2024 | 31103 | 0.790 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 18 | 0.780 |
Why?
| | Fatty Acids, Omega-3 | 4 | 2015 | 138 | 0.770 |
Why?
| | Microalgae | 2 | 2018 | 10 | 0.760 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2022 | 238 | 0.760 |
Why?
| | Sleep Medicine Specialty | 1 | 2021 | 9 | 0.750 |
Why?
| | Gonadal Steroid Hormones | 2 | 2020 | 134 | 0.750 |
Why?
| | Male | 81 | 2022 | 63544 | 0.740 |
Why?
| | Thiazolidinediones | 2 | 2015 | 136 | 0.740 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 6 | 2022 | 985 | 0.730 |
Why?
| | Phenotype | 15 | 2023 | 3063 | 0.720 |
Why?
| | Female | 79 | 2022 | 68562 | 0.710 |
Why?
| | Transients and Migrants | 2 | 2018 | 24 | 0.700 |
Why?
| | Fluticasone | 5 | 2021 | 90 | 0.690 |
Why?
| | Respiratory Mucosa | 5 | 2020 | 313 | 0.680 |
Why?
| | Heart Rate | 3 | 2013 | 808 | 0.670 |
Why?
| | Hydroxyurea | 1 | 2019 | 34 | 0.670 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2019 | 37 | 0.670 |
Why?
| | Respiratory Tract Diseases | 3 | 2017 | 152 | 0.660 |
Why?
| | Administration, Inhalation | 14 | 2021 | 676 | 0.650 |
Why?
| | Leptin | 3 | 2011 | 218 | 0.650 |
Why?
| | Social Class | 2 | 2021 | 259 | 0.650 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2019 | 10 | 0.640 |
Why?
| | Carotenoids | 1 | 2019 | 36 | 0.640 |
Why?
| | Stramenopiles | 1 | 2018 | 1 | 0.630 |
Why?
| | Adiponectin | 3 | 2011 | 232 | 0.630 |
Why?
| | Young Adult | 27 | 2021 | 12363 | 0.620 |
Why?
| | Biosynthetic Pathways | 1 | 2018 | 22 | 0.620 |
Why?
| | Age of Onset | 5 | 2018 | 494 | 0.610 |
Why?
| | Risk Factors | 22 | 2022 | 9832 | 0.610 |
Why?
| | Body Mass Index | 13 | 2024 | 2246 | 0.610 |
Why?
| | Pulmonary Eosinophilia | 1 | 2018 | 28 | 0.610 |
Why?
| | Biological Products | 1 | 2021 | 202 | 0.600 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1379 | 0.600 |
Why?
| | Nitrogen Dioxide | 4 | 2014 | 33 | 0.590 |
Why?
| | Immunoglobulin E | 6 | 2017 | 354 | 0.580 |
Why?
| | Bronchoalveolar Lavage Fluid | 10 | 2020 | 644 | 0.580 |
Why?
| | Biomedical Research | 2 | 2021 | 656 | 0.580 |
Why?
| | Pyridones | 1 | 2019 | 158 | 0.560 |
Why?
| | Critical Care | 2 | 2021 | 550 | 0.560 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 98 | 0.560 |
Why?
| | Acclimatization | 1 | 2018 | 161 | 0.550 |
Why?
| | Thinness | 3 | 2021 | 89 | 0.550 |
Why?
| | Nitrosative Stress | 1 | 2016 | 4 | 0.540 |
Why?
| | Fluorocarbons | 1 | 2018 | 109 | 0.540 |
Why?
| | Respiratory Tract Infections | 4 | 2016 | 373 | 0.520 |
Why?
| | Salmeterol Xinafoate | 3 | 2021 | 41 | 0.520 |
Why?
| | Triglycerides | 1 | 2018 | 519 | 0.520 |
Why?
| | Dyslipidemias | 1 | 2017 | 176 | 0.500 |
Why?
| | Biomarkers | 14 | 2021 | 3893 | 0.500 |
Why?
| | Environmental Monitoring | 6 | 2017 | 326 | 0.490 |
Why?
| | Soybean Oil | 2 | 2005 | 14 | 0.490 |
Why?
| | Adolescent | 33 | 2021 | 20355 | 0.490 |
Why?
| | Fish Oils | 2 | 2005 | 26 | 0.490 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 316 | 0.480 |
Why?
| | Fatty Acids, Omega-6 | 2 | 2015 | 48 | 0.470 |
Why?
| | United States | 24 | 2023 | 14078 | 0.460 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 614 | 0.450 |
Why?
| | Oxidation-Reduction | 3 | 2016 | 1013 | 0.450 |
Why?
| | Inflammation Mediators | 3 | 2014 | 504 | 0.450 |
Why?
| | Exhalation | 2 | 2020 | 39 | 0.440 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3054 | 0.440 |
Why?
| | Carbon Monoxide | 1 | 2013 | 67 | 0.430 |
Why?
| | Epithelial Cells | 7 | 2023 | 1060 | 0.430 |
Why?
| | Aged | 21 | 2020 | 22113 | 0.420 |
Why?
| | Health Status | 1 | 2017 | 751 | 0.420 |
Why?
| | Ornithine | 2 | 2023 | 25 | 0.420 |
Why?
| | Eczema | 1 | 2014 | 83 | 0.420 |
Why?
| | Child | 33 | 2023 | 20963 | 0.410 |
Why?
| | Morbidity | 3 | 2023 | 303 | 0.410 |
Why?
| | Hospital Mortality | 3 | 2020 | 858 | 0.410 |
Why?
| | Inhalation Exposure | 1 | 2013 | 109 | 0.410 |
Why?
| | Rhinitis | 1 | 2014 | 152 | 0.390 |
Why?
| | Lung Diseases, Obstructive | 1 | 2012 | 46 | 0.380 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 274 | 0.380 |
Why?
| | Air Pollutants, Occupational | 1 | 2012 | 35 | 0.380 |
Why?
| | Immunologic Factors | 1 | 2014 | 230 | 0.380 |
Why?
| | Prevalence | 7 | 2020 | 2557 | 0.370 |
Why?
| | Firefighters | 1 | 2012 | 39 | 0.370 |
Why?
| | Dust | 1 | 2012 | 100 | 0.370 |
Why?
| | Eosinophils | 5 | 2020 | 324 | 0.370 |
Why?
| | Double-Blind Method | 11 | 2019 | 1871 | 0.360 |
Why?
| | Comorbidity | 10 | 2023 | 1545 | 0.360 |
Why?
| | Bronchoconstriction | 2 | 2010 | 33 | 0.360 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2022 | 0.350 |
Why?
| | Quality of Life | 8 | 2023 | 2712 | 0.350 |
Why?
| | Pediatric Obesity | 1 | 2017 | 568 | 0.350 |
Why?
| | Intensive Care Units | 2 | 2020 | 738 | 0.340 |
Why?
| | Eosinophilia | 3 | 2020 | 207 | 0.340 |
Why?
| | Atherosclerosis | 1 | 2014 | 392 | 0.340 |
Why?
| | Airway Resistance | 1 | 2010 | 38 | 0.340 |
Why?
| | Sputum | 6 | 2019 | 309 | 0.330 |
Why?
| | Air Pollution, Indoor | 2 | 2017 | 139 | 0.330 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 65 | 0.330 |
Why?
| | Overweight | 3 | 2024 | 524 | 0.330 |
Why?
| | Alendronate | 2 | 2019 | 12 | 0.320 |
Why?
| | Spirometry | 4 | 2023 | 251 | 0.320 |
Why?
| | Hypersensitivity | 3 | 2022 | 277 | 0.320 |
Why?
| | Pneumocystis carinii | 1 | 2009 | 10 | 0.320 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2009 | 36 | 0.310 |
Why?
| | Heart Ventricles | 1 | 2014 | 779 | 0.310 |
Why?
| | Hydrogen Peroxide | 3 | 2022 | 310 | 0.310 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 1061 | 0.310 |
Why?
| | Precision Medicine | 3 | 2021 | 385 | 0.310 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2008 | 36 | 0.310 |
Why?
| | Health Services Accessibility | 2 | 2017 | 908 | 0.300 |
Why?
| | Health Services | 1 | 2009 | 108 | 0.300 |
Why?
| | Occupational Exposure | 1 | 2012 | 312 | 0.300 |
Why?
| | Mexico | 7 | 2013 | 188 | 0.300 |
Why?
| | Vasculitis | 1 | 2008 | 68 | 0.300 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2009 | 126 | 0.290 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 276 | 0.290 |
Why?
| | Child, Preschool | 16 | 2021 | 10565 | 0.290 |
Why?
| | Mucins | | | 71 | NaN |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 751 | 0.290 |
Why?
| | Aged, 80 and over | 7 | 2020 | 7074 | 0.290 |
Why?
| | Isoprostanes | 1 | 2007 | 5 | 0.280 |
Why?
| | Th2 Cells | 3 | 2019 | 170 | 0.280 |
Why?
| | Bronchi | 3 | 2018 | 253 | 0.280 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1507 | 0.280 |
Why?
| | Fatty Acids | 2 | 2021 | 416 | 0.280 |
Why?
| | Breath Tests | 4 | 2018 | 94 | 0.270 |
Why?
| | Schools | 6 | 2021 | 446 | 0.270 |
Why?
| | Albuterol | 5 | 2023 | 106 | 0.270 |
Why?
| | Patient Admission | 1 | 2008 | 185 | 0.270 |
Why?
| | Refugees | 2 | 2018 | 66 | 0.270 |
Why?
| | Cytokines | 5 | 2019 | 2008 | 0.270 |
Why?
| | Treatment Outcome | 8 | 2020 | 10299 | 0.260 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2670 | 0.260 |
Why?
| | Logistic Models | 4 | 2020 | 1980 | 0.250 |
Why?
| | Interleukin-13 | 4 | 2020 | 147 | 0.250 |
Why?
| | Societies, Medical | 5 | 2023 | 763 | 0.250 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5050 | 0.240 |
Why?
| | Fucosyltransferases | | | 33 | NaN |
Why?
| | Self Report | 2 | 2019 | 798 | 0.240 |
Why?
| | Cholecalciferol | 2 | 2016 | 59 | 0.230 |
Why?
| | Disease Progression | 7 | 2020 | 2612 | 0.230 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 75 | 0.230 |
Why?
| | Leukocyte Count | 4 | 2020 | 330 | 0.230 |
Why?
| | Prospective Studies | 8 | 2023 | 7131 | 0.230 |
Why?
| | Sex Factors | 4 | 2018 | 1952 | 0.230 |
Why?
| | Respiration, Artificial | 3 | 2020 | 605 | 0.220 |
Why?
| | Mexican Americans | 1 | 2004 | 111 | 0.220 |
Why?
| | Microbiota | 3 | 2022 | 727 | 0.210 |
Why?
| | Mitochondrial Diseases | | | 89 | NaN |
Why?
| | Insect Repellents | 1 | 2023 | 5 | 0.210 |
Why?
| | Oils, Volatile | 1 | 2023 | 6 | 0.210 |
Why?
| | Insect Bites and Stings | 1 | 2023 | 14 | 0.210 |
Why?
| | Animals | 11 | 2023 | 34733 | 0.210 |
Why?
| | Ixodes | 1 | 2023 | 13 | 0.210 |
Why?
| | Vital Capacity | 4 | 2021 | 284 | 0.210 |
Why?
| | Vitamin D Deficiency | 2 | 2016 | 179 | 0.210 |
Why?
| | Proof of Concept Study | 2 | 2019 | 63 | 0.210 |
Why?
| | Respiratory System | 3 | 2020 | 153 | 0.200 |
Why?
| | Housing | | | 132 | NaN |
Why?
| | Pilot Projects | 2 | 2019 | 1567 | 0.200 |
Why?
| | Reflex | 1 | 2023 | 67 | 0.200 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2019 | 173 | 0.200 |
Why?
| | Vagus Nerve | 1 | 2023 | 85 | 0.200 |
Why?
| | Aedes | 1 | 2023 | 57 | 0.200 |
Why?
| | Incidence | 5 | 2020 | 2658 | 0.200 |
Why?
| | Quercetin | 1 | 2022 | 11 | 0.200 |
Why?
| | Neurodegenerative Diseases | | | 107 | NaN |
Why?
| | Nutrition Surveys | 3 | 2018 | 259 | 0.200 |
Why?
| | Gene Expression Regulation | 3 | 2019 | 2522 | 0.190 |
Why?
| | Smoking | 3 | 2020 | 1507 | 0.190 |
Why?
| | Antioxidants | 4 | 2016 | 557 | 0.190 |
Why?
| | Nitro Compounds | 1 | 2021 | 6 | 0.190 |
Why?
| | Oleic Acids | 1 | 2021 | 10 | 0.190 |
Why?
| | Residence Characteristics | 1 | 2004 | 327 | 0.190 |
Why?
| | Hypersensitivity, Immediate | 2 | 2016 | 48 | 0.190 |
Why?
| | Geography | 2 | 2021 | 186 | 0.190 |
Why?
| | Waiting Lists | 1 | 2023 | 244 | 0.190 |
Why?
| | Life Style | 2 | 2023 | 463 | 0.190 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 319 | 0.180 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 59 | 0.180 |
Why?
| | Signal Transduction | 5 | 2020 | 4863 | 0.180 |
Why?
| | Arginase | 1 | 2021 | 30 | 0.180 |
Why?
| | Omalizumab | 1 | 2021 | 59 | 0.180 |
Why?
| | Public Policy | 1 | 2021 | 69 | 0.180 |
Why?
| | Public Health | 3 | 2018 | 498 | 0.180 |
Why?
| | Self-Management | 1 | 2023 | 159 | 0.180 |
Why?
| | Automobiles | 3 | 2011 | 19 | 0.180 |
Why?
| | Lung Transplantation | 1 | 2023 | 276 | 0.180 |
Why?
| | Symptom Flare Up | 1 | 2020 | 38 | 0.180 |
Why?
| | Patient Advocacy | 1 | 2021 | 73 | 0.180 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2018 | 93 | 0.180 |
Why?
| | Socioeconomic Factors | 4 | 2018 | 1212 | 0.180 |
Why?
| | Stakeholder Participation | 1 | 2021 | 76 | 0.180 |
Why?
| | Health Policy | 2 | 2021 | 364 | 0.180 |
Why?
| | Disulfides | 1 | 2021 | 95 | 0.180 |
Why?
| | Geographic Mapping | 1 | 2020 | 20 | 0.170 |
Why?
| | Geographic Information Systems | 1 | 2020 | 40 | 0.170 |
Why?
| | Mucin 5AC | | | 69 | NaN |
Why?
| | Case-Control Studies | 6 | 2020 | 3363 | 0.170 |
Why?
| | Neutrophils | 3 | 2020 | 1205 | 0.170 |
Why?
| | Trust | 1 | 2021 | 117 | 0.170 |
Why?
| | Chemotaxis | 1 | 2020 | 130 | 0.170 |
Why?
| | Soot | 3 | 2015 | 24 | 0.170 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 197 | 0.170 |
Why?
| | Poverty | | | 493 | NaN |
Why?
| | Dyspnea | 1 | 2022 | 239 | 0.170 |
Why?
| | Uncertainty | 1 | 2020 | 113 | 0.170 |
Why?
| | Puberty | 2 | 2018 | 143 | 0.170 |
Why?
| | Diet | 2 | 2019 | 1214 | 0.170 |
Why?
| | Muscarinic Antagonists | 1 | 2019 | 27 | 0.170 |
Why?
| | Age Factors | 5 | 2018 | 3145 | 0.170 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 50 | 0.170 |
Why?
| | Tissue and Organ Procurement | 1 | 2023 | 302 | 0.170 |
Why?
| | Th1 Cells | 2 | 2017 | 141 | 0.160 |
Why?
| | Gene Expression | 4 | 2018 | 1477 | 0.160 |
Why?
| | Mometasone Furoate | 1 | 2019 | 5 | 0.160 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 34 | 0.160 |
Why?
| | Nitric Oxide Synthase | 2 | 2019 | 240 | 0.160 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2353 | 0.160 |
Why?
| | Mucin-4 | 1 | 2019 | 4 | 0.160 |
Why?
| | Sialyltransferases | 1 | 2019 | 13 | 0.160 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 19 | 0.160 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2019 | 45 | 0.160 |
Why?
| | Saline Waters | 1 | 2018 | 1 | 0.160 |
Why?
| | Immunity | 2 | 2022 | 132 | 0.160 |
Why?
| | Cities | 4 | 2013 | 101 | 0.160 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2020 | 155 | 0.160 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 194 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2021 | 242 | 0.160 |
Why?
| | Interleukins | 1 | 2020 | 245 | 0.160 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1442 | 0.150 |
Why?
| | Immunoglobulin Fragments | 1 | 2018 | 16 | 0.150 |
Why?
| | Exercise Test | 1 | 2022 | 620 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 91 | 0.150 |
Why?
| | Moraxella | 1 | 2018 | 5 | 0.150 |
Why?
| | Weight Loss | 2 | 2023 | 727 | 0.150 |
Why?
| | Airway Remodeling | 2 | 2016 | 61 | 0.150 |
Why?
| | Porosity | 1 | 2018 | 92 | 0.150 |
Why?
| | DNA Methylation | 1 | 2023 | 601 | 0.150 |
Why?
| | Adsorption | 1 | 2018 | 138 | 0.150 |
Why?
| | Water | 2 | 2018 | 441 | 0.150 |
Why?
| | Retrospective Studies | 8 | 2023 | 14669 | 0.140 |
Why?
| | Silicon Dioxide | 1 | 2018 | 107 | 0.140 |
Why?
| | Corynebacterium | 1 | 2018 | 48 | 0.140 |
Why?
| | Cold Temperature | 1 | 2018 | 151 | 0.140 |
Why?
| | Surveys and Questionnaires | 6 | 2023 | 5396 | 0.140 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 594 | 0.140 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1227 | 0.140 |
Why?
| | Adaptive Clinical Trials as Topic | 3 | 2021 | 20 | 0.140 |
Why?
| | RNA, Messenger | 3 | 2020 | 2705 | 0.140 |
Why?
| | Quinolones | 1 | 2018 | 123 | 0.140 |
Why?
| | Volatile Organic Compounds | 1 | 2017 | 53 | 0.140 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 10 | 0.140 |
Why?
| | Voice Quality | 1 | 2016 | 16 | 0.140 |
Why?
| | Aminophenols | 1 | 2018 | 141 | 0.130 |
Why?
| | Ozone | 2 | 2015 | 110 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 262 | 0.130 |
Why?
| | Leukotriene Antagonists | 1 | 2016 | 43 | 0.130 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 78 | 0.130 |
Why?
| | Functional Food | 1 | 2016 | 2 | 0.130 |
Why?
| | Antigens, CD | 1 | 2019 | 479 | 0.130 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 333 | 0.130 |
Why?
| | Food Quality | 1 | 2016 | 10 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 168 | 0.130 |
Why?
| | Chemokines, CC | 2 | 2014 | 32 | 0.130 |
Why?
| | Vitamins | 2 | 2015 | 172 | 0.130 |
Why?
| | Pigments, Biological | 1 | 2016 | 16 | 0.130 |
Why?
| | Forced Expiratory Flow Rates | 1 | 2015 | 15 | 0.130 |
Why?
| | Crops, Agricultural | 1 | 2016 | 29 | 0.130 |
Why?
| | Zea mays | 1 | 2016 | 41 | 0.130 |
Why?
| | Bronchoconstrictor Agents | 1 | 2015 | 16 | 0.130 |
Why?
| | Vermont | 1 | 2015 | 5 | 0.130 |
Why?
| | Income | 1 | 2017 | 190 | 0.130 |
Why?
| | Ibuprofen | 1 | 2016 | 79 | 0.130 |
Why?
| | Methacholine Chloride | 1 | 2015 | 51 | 0.130 |
Why?
| | Bariatric Surgery | 1 | 2019 | 190 | 0.130 |
Why?
| | Anthocyanins | 1 | 2016 | 33 | 0.130 |
Why?
| | Bronchial Provocation Tests | 1 | 2015 | 50 | 0.130 |
Why?
| | Healthcare Disparities | 2 | 2023 | 571 | 0.130 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2015 | 6 | 0.120 |
Why?
| | Blood Platelets | 1 | 2019 | 372 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 596 | 0.120 |
Why?
| | Preventive Medicine | 1 | 2016 | 40 | 0.120 |
Why?
| | Seeds | 1 | 2016 | 84 | 0.120 |
Why?
| | Health Surveys | 2 | 2009 | 488 | 0.120 |
Why?
| | Metabolome | 1 | 2018 | 316 | 0.120 |
Why?
| | Mice | 7 | 2023 | 16585 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2018 | 491 | 0.120 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2015 | 2 | 0.120 |
Why?
| | Homocysteine | 1 | 2015 | 150 | 0.120 |
Why?
| | Chlamydomonas reinhardtii | 1 | 2014 | 5 | 0.120 |
Why?
| | Transportation | 1 | 2015 | 53 | 0.120 |
Why?
| | Azithromycin | 1 | 2015 | 92 | 0.120 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 110 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2539 | 0.120 |
Why?
| | Fibrinogen | 1 | 2015 | 160 | 0.120 |
Why?
| | Interleukin-27 | 1 | 2014 | 12 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 832 | 0.120 |
Why?
| | Body Weight | 1 | 2019 | 935 | 0.120 |
Why?
| | Pennsylvania | 4 | 2016 | 104 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2017 | 246 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 239 | 0.110 |
Why?
| | Pregnenediones | 1 | 2014 | 22 | 0.110 |
Why?
| | Lipids | 2 | 2015 | 614 | 0.110 |
Why?
| | Interleukin-6 | 2 | 2016 | 715 | 0.110 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2016 | 148 | 0.110 |
Why?
| | Photosynthesis | 1 | 2014 | 89 | 0.110 |
Why?
| | Cohort Studies | 8 | 2020 | 5410 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 246 | 0.110 |
Why?
| | Acetaminophen | 1 | 2016 | 255 | 0.110 |
Why?
| | Nitrogen | 1 | 2014 | 166 | 0.110 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5279 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2015 | 394 | 0.110 |
Why?
| | Cells, Cultured | 5 | 2020 | 4058 | 0.110 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 20 | 0.110 |
Why?
| | Receptors, Prostaglandin | 1 | 2013 | 22 | 0.110 |
Why?
| | Linear Models | 4 | 2018 | 823 | 0.110 |
Why?
| | Nutritional Status | 1 | 2015 | 327 | 0.100 |
Why?
| | Odds Ratio | 1 | 2015 | 1025 | 0.100 |
Why?
| | Dinoprost | 2 | 2009 | 30 | 0.100 |
Why?
| | Metallurgy | 1 | 2012 | 9 | 0.100 |
Why?
| | Chemokine CCL24 | 1 | 2012 | 11 | 0.100 |
Why?
| | Texas | 4 | 2017 | 234 | 0.100 |
Why?
| | Time Factors | 2 | 2015 | 6593 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4016 | 0.100 |
Why?
| | Cross-Over Studies | 3 | 2019 | 524 | 0.100 |
Why?
| | Particle Size | 3 | 2011 | 348 | 0.100 |
Why?
| | Macrophages, Alveolar | 3 | 2015 | 389 | 0.100 |
Why?
| | Mucin-5B | | | 217 | NaN |
Why?
| | Weight Gain | 1 | 2015 | 505 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2021 | 1241 | 0.100 |
Why?
| | Interferon-gamma | 1 | 2015 | 765 | 0.100 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 214 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1696 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 1858 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2019 | 1969 | 0.090 |
Why?
| | Leukotriene E4 | 1 | 2011 | 26 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2008 | 0.090 |
Why?
| | Research Design | 3 | 2021 | 1048 | 0.090 |
Why?
| | Mental Health | 1 | 2017 | 676 | 0.090 |
Why?
| | Glutathione Transferase | 2 | 2009 | 98 | 0.090 |
Why?
| | Functional Residual Capacity | 1 | 2010 | 7 | 0.090 |
Why?
| | Inhalation | 1 | 2010 | 30 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2020 | 2778 | 0.080 |
Why?
| | Alabama | 1 | 2009 | 37 | 0.080 |
Why?
| | Illinois | 1 | 2009 | 39 | 0.080 |
Why?
| | Nitrites | 1 | 2009 | 81 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 45 | 0.080 |
Why?
| | Nitrates | 1 | 2009 | 87 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2017 | 1165 | 0.080 |
Why?
| | Tyrosine | 1 | 2009 | 219 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2008 | 23 | 0.080 |
Why?
| | Gases | 1 | 2009 | 46 | 0.080 |
Why?
| | Chlorine | 1 | 2009 | 64 | 0.080 |
Why?
| | Depression | 2 | 2016 | 1290 | 0.080 |
Why?
| | California | 1 | 2009 | 403 | 0.070 |
Why?
| | Mice, Obese | 1 | 2007 | 55 | 0.070 |
Why?
| | Mutation | 1 | 2018 | 3674 | 0.070 |
Why?
| | Pneumonia | 2 | 2020 | 613 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3351 | 0.070 |
Why?
| | Employer Health Costs | 1 | 2006 | 4 | 0.070 |
Why?
| | Glutathione | 1 | 2009 | 333 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2009 | 564 | 0.070 |
Why?
| | Anti-Retroviral Agents | 1 | 2009 | 230 | 0.070 |
Why?
| | PPAR gamma | 1 | 2007 | 182 | 0.070 |
Why?
| | Medication Adherence | 2 | 2023 | 576 | 0.070 |
Why?
| | Phagocytosis | 1 | 2008 | 363 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2009 | 698 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2021 | 259 | 0.060 |
Why?
| | Protein Isoforms | 2 | 2019 | 369 | 0.060 |
Why?
| | Acute Lung Injury | 1 | 2009 | 280 | 0.060 |
Why?
| | Urban Health | 1 | 2005 | 79 | 0.060 |
Why?
| | Bronchoscopy | 3 | 2012 | 220 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 389 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1719 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2008 | 328 | 0.060 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 521 | 0.060 |
Why?
| | Child Day Care Centers | 1 | 2005 | 34 | 0.060 |
Why?
| | Homeostasis | 1 | 2009 | 604 | 0.060 |
Why?
| | Health Expenditures | 1 | 2006 | 187 | 0.060 |
Why?
| | Infant | 5 | 2018 | 9097 | 0.060 |
Why?
| | Biopsy | 1 | 2008 | 1098 | 0.060 |
Why?
| | Glycosylation | | | 144 | NaN |
Why?
| | Renal Dialysis | 1 | 2008 | 417 | 0.060 |
Why?
| | Cost of Illness | 1 | 2006 | 296 | 0.060 |
Why?
| | Interleukin-5 | | | 38 | NaN |
Why?
| | Survival Rate | 1 | 2009 | 1894 | 0.060 |
Why?
| | Chemokine CCL26 | 2 | 2014 | 9 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 255 | 0.060 |
Why?
| | Hormones | | | 139 | NaN |
Why?
| | Bronchoalveolar Lavage | 2 | 2015 | 92 | 0.060 |
Why?
| | Up-Regulation | 2 | 2020 | 850 | 0.060 |
Why?
| | Nursing Homes | 1 | 2005 | 154 | 0.060 |
Why?
| | Prognosis | 2 | 2010 | 3801 | 0.050 |
Why?
| | Epigenomics | 1 | 2023 | 111 | 0.050 |
Why?
| | Recurrence | 2 | 2016 | 1016 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2424 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 30 | 0.050 |
Why?
| | Americas | 1 | 2022 | 19 | 0.050 |
Why?
| | Brazil | 1 | 2022 | 102 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2005 | 233 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2013 | 426 | 0.050 |
Why?
| | Latin America | 1 | 2022 | 83 | 0.050 |
Why?
| | Biology | 1 | 2023 | 82 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 517 | 0.050 |
Why?
| | Glycocholic Acid | 1 | 2021 | 6 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2021 | 10 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 73 | 0.050 |
Why?
| | Ursodeoxycholic Acid | 1 | 2021 | 21 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2744 | 0.050 |
Why?
| | Respiratory Hypersensitivity | 1 | 2021 | 64 | 0.050 |
Why?
| | Reactive Oxygen Species | | | 579 | NaN |
Why?
| | Molecular Targeted Therapy | | | 381 | NaN |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.050 |
Why?
| | Status Asthmaticus | 1 | 2020 | 11 | 0.050 |
Why?
| | Expectorants | 1 | 2021 | 24 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 173 | 0.050 |
Why?
| | Canada | 1 | 2022 | 355 | 0.040 |
Why?
| | International Cooperation | 2 | 2011 | 173 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 27 | 0.040 |
Why?
| | New York City | 1 | 2020 | 82 | 0.040 |
Why?
| | Dermatitis, Atopic | | | 335 | NaN |
Why?
| | Antibodies, Viral | | | 607 | NaN |
Why?
| | Advisory Committees | 1 | 2021 | 231 | 0.040 |
Why?
| | Altitude | 2 | 2016 | 451 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 241 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 266 | 0.040 |
Why?
| | Research | 1 | 2023 | 416 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 159 | 0.040 |
Why?
| | Stroke | 1 | 2008 | 1111 | 0.040 |
Why?
| | Patient Discharge | 1 | 2005 | 862 | 0.040 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2019 | 47 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 340 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1206 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1024 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 327 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 261 | 0.040 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 37 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2272 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 315 | 0.040 |
Why?
| | Nose | 1 | 2018 | 64 | 0.040 |
Why?
| | Growth | 1 | 2018 | 57 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2018 | 89 | 0.040 |
Why?
| | Epithelium | 1 | 2019 | 313 | 0.040 |
Why?
| | Chlorobenzenes | 1 | 2017 | 9 | 0.040 |
Why?
| | Toluene | 1 | 2017 | 11 | 0.040 |
Why?
| | Cyclohexenes | 1 | 2017 | 7 | 0.040 |
Why?
| | Pentanes | 1 | 2017 | 10 | 0.040 |
Why?
| | Xylenes | 1 | 2017 | 7 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 2044 | 0.040 |
Why?
| | Benzene | 1 | 2017 | 14 | 0.040 |
Why?
| | Terpenes | 1 | 2017 | 21 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 349 | 0.040 |
Why?
| | Oils | 1 | 2017 | 20 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 320 | 0.030 |
Why?
| | Communication | 1 | 2023 | 844 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 102 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2016 | 36 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1334 | 0.030 |
Why?
| | Biomass | 1 | 2017 | 127 | 0.030 |
Why?
| | Crop Production | 1 | 2016 | 1 | 0.030 |
Why?
| | Succinates | 1 | 2016 | 22 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 463 | 0.030 |
Why?
| | Wound Healing | 1 | 2019 | 310 | 0.030 |
Why?
| | Southwestern United States | 1 | 2016 | 93 | 0.030 |
Why?
| | Plant Breeding | 1 | 2016 | 18 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 361 | 0.030 |
Why?
| | Glucosides | 1 | 2016 | 37 | 0.030 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2015 | 3 | 0.030 |
Why?
| | Receptors, Interleukin-17 | 1 | 2015 | 5 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 181 | 0.030 |
Why?
| | Vaccination | | | 1362 | NaN |
Why?
| | Stress, Psychological | | | 1051 | NaN |
Why?
| | Hospital Costs | 1 | 2016 | 117 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 186 | 0.030 |
Why?
| | Photosystem I Protein Complex | 1 | 2014 | 2 | 0.030 |
Why?
| | Hydroxylation | 1 | 2015 | 32 | 0.030 |
Why?
| | Proton-Motive Force | 1 | 2014 | 6 | 0.030 |
Why?
| | Chlorophyll | 1 | 2014 | 14 | 0.030 |
Why?
| | Thylakoids | 1 | 2014 | 5 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 129 | 0.030 |
Why?
| | Carbon Cycle | 1 | 2014 | 16 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 101 | 0.030 |
Why?
| | Fever | 1 | 2016 | 301 | 0.030 |
Why?
| | Industry | 1 | 2015 | 64 | 0.030 |
Why?
| | Starch | 1 | 2014 | 22 | 0.030 |
Why?
| | Critical Illness | 1 | 2020 | 765 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2017 | 339 | 0.030 |
Why?
| | Chemokine CXCL9 | 1 | 2014 | 23 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2016 | 291 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 107 | 0.030 |
Why?
| | STAT Transcription Factors | 1 | 2014 | 14 | 0.030 |
Why?
| | Species Specificity | 1 | 2016 | 567 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 175 | 0.030 |
Why?
| | Exons | 1 | 2015 | 330 | 0.030 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2014 | 57 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1291 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2016 | 202 | 0.030 |
Why?
| | Sepsis | 1 | 2020 | 566 | 0.030 |
Why?
| | Fluorescence | 1 | 2014 | 159 | 0.030 |
Why?
| | Docosahexaenoic Acids | 1 | 2015 | 81 | 0.030 |
Why?
| | Carbon Isotopes | 1 | 2014 | 123 | 0.030 |
Why?
| | Plant Proteins | 1 | 2014 | 92 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 863 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2015 | 373 | 0.030 |
Why?
| | Temperature | 1 | 2017 | 634 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 763 | 0.030 |
Why?
| | Colorado | | | 4471 | NaN |
Why?
| | Acute Disease | 1 | 2016 | 984 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2768 | 0.030 |
Why?
| | Risk | 1 | 2016 | 871 | 0.030 |
Why?
| | Lipocalins | 1 | 2013 | 36 | 0.030 |
Why?
| | Treatment Failure | 1 | 2014 | 347 | 0.030 |
Why?
| | RNA Interference | 1 | 2015 | 448 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2013 | 67 | 0.030 |
Why?
| | Steel | 1 | 2012 | 7 | 0.030 |
Why?
| | Meteorological Concepts | 1 | 2012 | 6 | 0.030 |
Why?
| | Liver | 1 | 2021 | 1848 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 872 | 0.030 |
Why?
| | Chemokine CCL11 | 1 | 2012 | 26 | 0.030 |
Why?
| | Spatio-Temporal Analysis | 1 | 2012 | 27 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 962 | 0.030 |
Why?
| | Exercise | 1 | 2024 | 1931 | 0.020 |
Why?
| | Heart Failure | 1 | 2005 | 2145 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 637 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 790 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 328 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2011 | 50 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3297 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 880 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1981 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 776 | 0.020 |
Why?
| | Pain | 1 | 2016 | 770 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 828 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 813 | 0.020 |
Why?
| | Seasons | 1 | 2012 | 508 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 921 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 949 | 0.020 |
Why?
| | Chemical Hazard Release | 1 | 2009 | 1 | 0.020 |
Why?
| | Railroads | 1 | 2009 | 5 | 0.020 |
Why?
| | Glutathione Reductase | 1 | 2009 | 22 | 0.020 |
Why?
| | Malondialdehyde | 1 | 2009 | 28 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2009 | 12 | 0.020 |
Why?
| | South Carolina | 1 | 2009 | 41 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 837 | 0.020 |
Why?
| | Glutathione Peroxidase | 1 | 2009 | 42 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 230 | 0.020 |
Why?
| | Voice Disorders | 1 | 2009 | 21 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2008 | 14 | 0.020 |
Why?
| | Cough | 1 | 2009 | 118 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 551 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3106 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4939 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2013 | 806 | 0.020 |
Why?
| | Office Visits | 1 | 2006 | 85 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 299 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2006 | 254 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2006 | 511 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1632 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2485 | 0.010 |
Why?
|
|
Holguin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|